ArticleCurrent infectious disease reports2002
The Pathophysiology and Treatment of Candida Sepsis.
Article in Current infectious disease reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Seselin ameliorates inflammation via targeting Jak2 to suppress the proinflammatory phenotype of macrophages.British journal of pharmacology · 2019Article
- Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice.Scientific reports · 2016Article
- Hosting infection: experimental models to assay Candida virulence.International journal of microbiology · 2012Article
- Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis.PloS one · 2012Article
- An insight into the antifungal pipeline: selected new molecules and beyond.Nature reviews. Drug discovery · 2010Review
- The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.Infection and immunity · 2006Article
- A novel glyco-conjugate vaccine against fungal pathogens.The Journal of experimental medicine · 2005Article
- The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.Infection and immunity · 2005Article
- Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.Infection and immunity · 2005Article
- Fungal Endocarditis.Current infectious disease reports · 2004Article
- Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis.Infection and immunity · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis can occur during disseminated candidiasis, but its pathogenesis differs from that caused by typical prokaryotic pathogens. Complex interactions between defects in host defense and "relative" virulence factors expressed by Candida lead to dissemination of the saprophyte to parenchymal organs, and subsequently to onset of multiorgan failure. This review focuses first on the pathophysiology of Candida sepsis, detailing current understanding of host-pathogen interactions. We then consider the choice of antifungal and supportive treatments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.